They presented their findings at the SHEA Spring 2018 Conference, April 18 to April 20 in Portland, Ore.
Researchers examined pathogen and susceptibility data for CLABSI CRE reported to the CDC’s National Healthcare Safety Network in 2015-2016. They studied 13,996 reports of CLABSIs due to CRE from long-term and short-term care facilities.
Short-term acute care hospitals reported 6,438 and 6,113 CRE-associated CLABSIs in 2015 and 2016 respectively. They tested 77 percent of all isolates for carbapenem resistance and the overall resistance percentage increased from 4.7 percent in 2015 to 5.3 percent in 2016.
Long-term acute care hospitals reported 787 CRE-related CLABSIs in 2015 and 658 in 2016. They tested approximately 88 percent of isolates, and while the overall resistance percentage in long-term facilities was much higher than in short-term care hospitals, the percentage decreased from 18.5 percent in 2015 to 15.8 percent in 2016.
“Although a decrease was observed, CLABSI CRE is higher in [long-term acute care hospitals] than in [short-term acute care hospitals]. This could be explained by different patient populations and levels of care between the settings,” the study authors concluded.
More articles on healthcare quality:
Study: 1 in 4 NYC mice carry drug-resistant bacteria
California fines Memorial Medical Center $71k after patient death
25 teaching hospitals with the most safety violations
